Gastric cancer heterogeneity profoundly impacts clinical outcomes, yet the molecular underpinnings remain incompletely characterized. Here we present a comprehensive single-cell atlas of gastric cancer, integrating five cohorts comprising 101 samples and 327,471 cells. Unsupervised clustering delineated seven transcriptionally distinct tumor cell populations. Among these, an ITGB1-expressing subpopulation displayed hallmarks of epithelial-mesenchymal transition and demonstrated robust associations with metastatic progression and adverse prognosis. Leveraging the ITGB1 + transcriptional signature, we stratified patients into three molecular classes: C1 (metabolism-dominant), C2 (proliferation-dominant), and C3 (invasion-dominant). C3 tumors exhibited pronounced metastatic capacity, stemness features, and immunosuppressive microenvironmental remodeling, with five-year survival of merely 23%. Mechanistic interrogation identified INMT (Indolethylamine N-Methyltransferase) as a central driver of the aggressive C3 phenotype. Genetic ablation of INMT attenuated proliferative and invasive behaviors in vitro and suppressed tumor growth in vivo. Structure-based virtual screening nominated Savolitinib as a candidate INMT-targeting agent, a prediction validated through molecular dynamics simulations demonstrating stable binding interactions. Pharmacological INMT inhibition recapitulated the phenotypes observed with genetic knockdown, reducing tumor burden in xenograft models. Our work establishes a single-cell-resolved molecular taxonomy for gastric cancer, elucidates the mechanistic connection between epithelial-mesenchymal transition programming and metastatic dissemination, and positions INMT as an actionable therapeutic vulnerability—collectively advancing the framework for precision oncology in this disease.
Xu et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: